Bicara Therapeutics Inc. BCAX
We take great care to ensure that the data presented and summarized in this overview for Bicara Therapeutics Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in BCAX
Top Purchases
Top Sells
About BCAX
Insider Transactions at BCAX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 17
2024
|
James E Flynn > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
70,000
+3.75%
|
$1,260,000
$18.0 P/Share
|
|
Sep 17
2024
|
James E Flynn > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,725,174
+50.0%
|
-
|
|
Sep 16
2024
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
1,833,000
+16.76%
|
$32,994,000
$18.0 P/Share
|
|
Sep 16
2024
|
Ra Capital Management, L.P. |
BUY
Conversion of derivative security
|
Indirect |
5,122,993
+50.0%
|
-
|
|
Sep 16
2024
|
Tpg Gp A, LLC |
BUY
Conversion of derivative security
|
Indirect |
1,960,425
+50.0%
|
-
|
|
Sep 16
2024
|
Fil LTD |
BUY
Conversion of derivative security
|
Indirect |
1,013,853
+41.23%
|
-
|
|
Sep 16
2024
|
Fmr LLC |
BUY
Conversion of derivative security
|
Indirect |
1,115,333
+41.88%
|
-
|
|
Sep 16
2024
|
Kiran Mazumdar Shaw |
BUY
Conversion of derivative security
|
Indirect |
6,165,428
+49.84%
|
-
|
|
Sep 16
2024
|
Biocon LTD |
BUY
Conversion of derivative security
|
Indirect |
5,408,140
+49.67%
|
-
|
Last 12 Months Summary
Buy / Acquisition
24.4M
Shares
From
9
Insiders
| Conversion of derivative security | 22.5M shares |
|---|---|
| Open market or private purchase | 1.9M shares |
Sell / Disposition
0
Shares
From
0
Insiders